Clinical Cancer Research, Vol 4, Issue 5 1227-1234, Copyright © 1998 by American Association for Cancer Research

ARTICLES

p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site

HJ Lenz, KD Danenberg, CG Leichman, B Florentine, PG Johnston, S Groshen, L Zhou, YP Xiong, PV Danenberg and LP Leichman
Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, University of Southern California School of Medicine, Los Angeles 90033, USA. lenz@hsc.usc.edu

We initiated a retrospective study to determine whether p53 status and thymidylate synthase (TS) protein expression in primary colon tumors influence recurrence and survival for patients with stage II colon cancer. Tumor specimens from 45 consecutive untreated patients with stage II colon cancer were examined for p53 and TS protein expression using immunohistochemistry. The median follow-up was 5.1 years. Eighteen patients had left-sided tumors, and 27 had right-sided tumors. Fourteen of 45 patients (31%) developed recurrence. p53 overexpression was detected in the tumors of 18 patients (40%); 10 patients (55%) with p53 overexpression recurred; and 4 of 27 (15%) without evidence of p53 overexpression recurred (P = 0.002). High TS expression was detected in the tumors of 16 patients (36%): 8 patients (50%) with high TS expression recurred, and 6 patients (21%) with low TS expression recurred (P = 0.027). Patients with p53 overexpression had a significantly poorer survival than did those patients without p53 overexpression (P < 0.001). High TS expression was associated with poor survival (P = 0.004). p53 overexpression and high TS expression were significantly associated with left-sided tumors (P = 0.003 and P = 0.022). Thirteen of 16 patients (81%) with high TS expression also overexpressed p53, and 24 of 29 patients (81%) with low TS expression did not manifest p53 overexpression (P < 0.001). p53 and TS expression in primary stage II colon cancer are associated and appear to influence recurrence and survival. In this pilot study, left-sided tumors demonstrate significantly more p53 overexpression and significantly higher TS expression than do right-sided tumors, which may explain the significantly poorer survival for patients with left-sided tumors.

This article has been cited by other articles:

				P. Ceppi, M. Volante, A. Ferrero, L. Righi, I. Rapa, R. Rosas, A. Berruti, L. Dogliotti, G. V. Scagliotti, and M. Papotti Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors Clin. Cancer Res., February 15, 2008; 14(4): 1059 - 1064. [Abstract] [Full Text] [PDF]

				L. Bottarelli, C. Azzoni, F. Necchi, C. Lagrasta, E. Tamburini, T. D'Adda, S. Pizzi, L. Sarli, G. Rindi, and C. Bordi Sex Chromosome Alterations Associate with Tumor Progression in Sporadic Colorectal Carcinomas Clin. Cancer Res., August 1, 2007; 13(15): 4365 - 4370. [Abstract] [Full Text] [PDF]

				G. P. Kim, L. H. Colangelo, H. S. Wieand, S. Paik, I. R. Kirsch, N. Wolmark, and C. J. Allegra Prognostic and Predictive Roles of High-Degree Microsatellite Instability in Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J. Clin. Oncol., March 1, 2007; 25(7): 767 - 772. [Abstract] [Full Text] [PDF]

				S Popat, Z Chen, D Zhao, H Pan, N Hearle, I Chandler, Y Shao, W Aherne, and R. Houlston A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer Ann. Onc., December 1, 2006; 17(12): 1810 - 1817. [Abstract] [Full Text] [PDF]

				B. Rubio-Viqueira, A. Jimeno, G. Cusatis, X. Zhang, C. Iacobuzio-Donahue, C. Karikari, C. Shi, K. Danenberg, P. V. Danenberg, H. Kuramochi, et al. An In vivo Platform for Translational Drug Development in Pancreatic Cancer Clin. Cancer Res., August 1, 2006; 12(15): 4652 - 4661. [Abstract] [Full Text] [PDF]

				V. Garcia, J. M. Garcia, C. Pena, J. Silva, G. Dominguez, A. Hurtado, I. Alonso, R. Rodriguez, M. Provencio, and F. Bonilla Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin. Cancer Res., April 1, 2006; 12(7): 2095 - 2100. [Abstract] [Full Text] [PDF]

				K. Ohrling, D. Edler, M. Hallstrom, P. Ragnhammar, and H. Blomgren Detection of Thymidylate Synthase Expression in Lymph Node Metastases of Colorectal Cancer Can Improve the Prognostic Information J. Clin. Oncol., August 20, 2005; 23(24): 5628 - 5634. [Abstract] [Full Text] [PDF]

				W. L. Allen and P. G. Johnston Role of Genomic Markers in Colorectal Cancer Treatment J. Clin. Oncol., July 10, 2005; 23(20): 4545 - 4552. [Abstract] [Full Text] [PDF]

				T. Lecomte, J.-M. Ferraz, F. Zinzindohoue, M.-A. Loriot, D.-A. Tregouet, B. Landi, A. Berger, P.-H. Cugnenc, R. Jian, P. Beaune, et al. Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy Clin. Cancer Res., September 1, 2004; 10(17): 5880 - 5888. [Abstract] [Full Text] [PDF]

				S. Popat, A. Matakidou, and R. S. Houlston Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis J. Clin. Oncol., February 1, 2004; 22(3): 529 - 536. [Abstract] [Full Text] [PDF]

				F. Graziano and S. Cascinu Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann. Onc., July 1, 2003; 14(7): 1026 - 1038. [Abstract] [Full Text] [PDF]

				P. G. Johnston, A. B. Benson III, P. Catalano, M. S. Rao, P. J. O'Dwyer, and C. J. Allegra Thymidylate Synthase Protein Expression in Primary Colorectal Cancer: Lack of Correlation With Outcome and Response to Fluorouracil in Metastatic Disease Sites J. Clin. Oncol., March 1, 2003; 21(5): 815 - 819. [Abstract] [Full Text] [PDF]

				C. Allegra and D. Sargent Molecular Diagnostics: Assays, Tissues, Progress, and Pitfalls J. Clin. Oncol., February 1, 2003; 21(3): 395 - 396. [Full Text] [PDF]

				M. Gonen, A. Hummer, A. Zervoudakis, D. Sullivan, Y. Fong, D. Banerjee, D. Klimstra, C. Cordon-Cardo, J. Bertino, and N. Kemeny Thymidylate Synthase Expression in Hepatic Tumors Is a Predictor of Survival and Progression in Patients With Resectable Metastatic Colorectal Cancer J. Clin. Oncol., February 1, 2003; 21(3): 406 - 412. [Abstract] [Full Text] [PDF]

				C. J. Allegra, S. Paik, L. H. Colangelo, A. L. Parr, I. Kirsch, G. Kim, P. Klein, P. G. Johnston, N. Wolmark, and H. S. Wieand Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J. Clin. Oncol., January 15, 2003; 21(2): 241 - 250. [Abstract] [Full Text] [PDF]

				A. J. Bilchik, D. T. Nora, S. Saha, R. Turner, D. Wiese, C. Kuo, X. Ye, D. L. Morton, and D. S. B. Hoon The Use of Molecular Profiling of Early Colorectal Cancer to Predict Micrometastases Arch Surg, December 1, 2002; 137(12): 1377 - 1383. [Abstract] [Full Text] [PDF]

				D. Edler, B. Glimelius, M. Hallstrom, A. Jakobsen, P. G. Johnston, I. Magnusson, P. Ragnhammar, and H. Blomgren Thymidylate Synthase Expression in Colorectal Cancer: A Prognostic and Predictive Marker of Benefit From Adjuvant Fluorouracil-Based Chemotherapy J. Clin. Oncol., April 1, 2002; 20(7): 1721 - 1728. [Abstract] [Full Text] [PDF]

				C. J. Allegra, A. L. Parr, L. E. Wold, M. R. Mahoney, D. J. Sargent, P. Johnston, P. Klein, K. Behan, M. J. O'Connell, R. Levitt, et al. Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer J. Clin. Oncol., April 1, 2002; 20(7): 1735 - 1743. [Abstract] [Full Text] [PDF]

				H H J Backus, C J Van Groeningen, W Vos, D F Dukers, E Bloemena, D Wouters, H M Pinedo, and G J Peters Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases J. Clin. Pathol., March 1, 2002; 55(3): 206 - 211. [Abstract] [Full Text] [PDF]

				Y. Shirota, J. Stoehlmacher, J. Brabender, Y.-P. Xiong, H. Uetake, K. D. Danenberg, S. Groshen, D. D. Tsao-Wei, P. V. Danenberg, and H.-J. Lenz ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy J. Clin. Oncol., December 1, 2001; 19(23): 4298 - 4304. [Abstract] [Full Text]

				J. L. Grem, K. D. Danenberg, K. Behan, A. Parr, L. Young, P. V. Danenberg, D. Nguyen, J. Drake, A. Monks, and C. J. Allegra Thymidine Kinase, Thymidylate Synthase, and Dihydropyrimidine Dehydrogenase Profiles of Cell Lines of the National Cancer Institute's Anticancer Drug Screen Clin. Cancer Res., April 1, 2001; 7(4): 999 - 1009. [Abstract] [Full Text]

				C. M. Ulrich, J. Bigler, C. M. Velicer, E. A. Greene, F. M. Farin, and J. D. Potter Searching Expressed Sequence Tag Databases: Discovery and Confirmation of a Common Polymorphism in the Thymidylate Synthase Gene Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1381 - 1385. [Abstract] [Full Text]

				R. D. Ladner, F. J. Lynch, S. Groshen, Y. P. Xiong, A. Sherrod, S. J. Caradonna, J. Stoehlmacher, and H.-J. Lenz dUTP Nucleotidohydrolase Isoform Expression in Normal and Neoplastic Tissues: Association with Survival and Response to 5-Fluorouracil in Colorectal Cancer Cancer Res., July 1, 2000; 60(13): 3493 - 3503. [Abstract] [Full Text]

				D. Edler, M. Hallström, P. G. Johnston, I. Magnusson, P. Ragnhammar, and H. Blomgren Thymidylate Synthase Expression: An Independent Prognostic Factor for Local Recurrence, Distant Metastasis, Disease-free and Overall Survival in Rectal Cancer Clin. Cancer Res., April 1, 2000; 6(4): 1378 - 1384. [Abstract] [Full Text]

				D. Edler, U. Kressner, P. Ragnhammar, P. G. Johnston, I. Magnusson, B. Glimelius, L. Påhlman, G. Lindmark, and H. Blomgren Immunohistochemically Detected Thymidylate Synthase in Colorectal Cancer: An Independent Prognostic Factor of Survival Clin. Cancer Res., February 1, 2000; 6(2): 488 - 492. [Abstract] [Full Text]

				Y. Ishikawa, T. Kubota, Y. Otani, M. Watanabe, T. Teramoto, K. Kumai, M. Kitajima, T. Takechi, H. Okabe, and M. Fukushima Dihydropyrimidine Dehydrogenase Activity and Messenger RNA Level May Be Related to the Antitumor Effect of 5-Fluorouracil on Human Tumor Xenografts in Nude Mice Clin. Cancer Res., April 1, 1999; 5(4): 883 - 889. [Abstract] [Full Text] [PDF]